tirzepatide surpass-4 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Lilly's tirzepatide achieves all primary

Oral peptide delivery has demonstrated similarly strong upward momentum

The first enzyme, glutamatecysteine ligase (GCL) formerly called -glutamylcysteine synthase (GCS) is the rate-limiting enzyme

This tailored approach helps maximize the chances of success

Britta Reierson , MD, FAAFP, a board-certified family physician and obesity medicine specialist at knownwell, a metabolic health company , cites a national Michigan Medicine survey that shows that up to 60,000 young adults are using GLP-1s on a regular basis, compared to 8,700 a month in 2020

Concerns about bone health in patients taking Ozempic primarily relate to the rapid weight loss that can occur during treatment, rather than a direct pharmacological effect of the medication on bone tissue